ADA Scientific Sessions 2025 Abstract

Glucagon-Like Peptide 1 Receptor Agonists and the Risk of Motility-Related Gastrointestinal Adverse Events—A Cohort Study

By Wajd Alkabbani, Salvatore Crisafulli, Julie M. Paik, Elisabetta Patorno

Study in peopleInterventions

The paper

Wajd Alkabbani, Salvatore Crisafulli, Julie M. Paik, Elisabetta Patorno

Boston

ADA Scientific Sessions 2025 Abstract, 13 Jun 2025

Presented at ADA Scientific Sessions 2025, poster 768-P

doi.org/10.2337/db25-768-p

Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes & Vascular Disease Research4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes, Obesity & Metabolism8 Oct 2026
Diabetes drug class linked to slightly less frailty progression
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes